Table 2. Treatment characteristics of the eligible studies.
| Study | Pathologic stage | Chemotherapy regimens | Chemotherapy dosage (mg/m2) | No. of planned cycles | Median follow-up, range (months) |
|---|---|---|---|---|---|
| Skinner [17] | T3-4, Nany, M0 | CAP | C 100, A 60, P 600 | 4 | 168 overall |
| Studer [18] | T1-4a, M0 | C | C 90 | 3 | 69 overall |
| Freiha [9] | T3b-4, Nany, M0 | CMV | C 100, M 30, V 4 | 4 | 62, 26-94 overall |
| Bono [19] | T2-4a, N0, M0 | CM | C 70, M 40 | 4 | 69 overall |
| Otto [20] | T3, N1-2, M0 | MVEC | M 30, V 3, E 45, C 70 | 3 | 3.62 yr overall |
| Lehmann [11] | T3-4a, Nany, M0 | CM vs MVEC | C 70, M 40 M 30, V 3, E 45, C 70 |
3 | 42 overall |
| Lehmann [12] | T3-4a, Nany, M0 | MVAC or MVEC | M 30, V 3, A 40, C 70 M 30, V 3, E 45, C 70 |
3 | Control: 57 ACH: 54 |
| Paz-Ares [21] | T3-4, Nany, M0 | GCP | G 1000, C 70, P 80 | 4 | 30, 1-95 overall |
| Stadler [13] | T1-2, N0, M0 | MVAC | NA | 3 | 5.4 yr overall |
| Cognetti [14] | T2-4, Nany, M0 | GC | G 1000, C 70 | 4 | 35, 15-57 (IQR) overall |
| Sternberg [15] | T3-4, Nany, M0 | (high dose) MVAC or GC | M 30, V 3, A 30, C 70 G 1000, C 70 |
4 | Control: 7.2 yr, 5.6-8.7 yr (IQR) ACH: 7 yr, 5.2-8.7 yr (IQR) |
CAP: cisplatin, doxorubicin and cyclophosphamide, C: cisplatin, CMV: cisplatin, methotrexate and vinblastine, CM: cisplatin and methotrexate, MVEC: methotrexate, vinblastine, epirubicin and cisplatin, MVAC: methotrexate, vinblastine, doxorubicin and cisplatin, ACH: adjuvant chemotherapy, GCP: gemcitabine, cisplatin and paclitaxel, GC: gemcitabine and cisplatin, IQR: interquartile range.